December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

4.910 +0.061 (+1.25%)
Streaming Delayed Price Updated: 3:06 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
Via ACCESSWIRE
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning! 
Via InvestorPlace
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Via ACCESSWIRE
News headline image
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
Via ACCESSWIRE
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
News headline image
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
Via ACCESSWIRE
News headline image
Aptevo Therapeutics: Q2 Earnings Insights ↗
  Aptevo Therapeutics (NASDAQ:APVO) reported its Q2 earnings results on Thursday, August 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
Via ACCESSWIRE
News headline image
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date 
From Aptevo Therapeutics
Via AccessWire
News headline image
Recap: Aptevo Therapeutics Q1 Earnings ↗
Aptevo Therapeutics (NASDAQ:APVO) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Are Aptevo Therapeutics Shares Trading Higher Today? ↗
Aptevo Therapeutics Inc (NASDAQ: APVO)  
Via Benzinga
News headline image
91 Biggest Movers From Friday ↗
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
News headline image
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
News headline image
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Earnings Perspective: Return On Capital Employed ↗
According to Benzinga Pro data, during Q4, Aptevo Therapeutics (NASDAQ:APVO) posted sales of $3.67 million. Earnings were up 10.36%, but Aptevo Therapeutics still reported an... 
Via Benzinga
News headline image
63 Biggest Movers From Yesterday ↗
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Nasdaq Rises 150 Points; Emclaire Financial Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Nasdaq composite gaining over 150 points on Thursday. The Dow traded up 0.76% to 34,621.33 while the NASDAQ rose 1.19... 
Via Benzinga
News headline image
Why Did Aptevo Therapeutics Stock Jump 25% Today? ↗
Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher Thursday after the company reported 2021 financial results. Aptevo said royalty revenue totaled $... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) stock increased by 26.3% to $1.73 during Thursday's regular session. The current volume of 55.2 million shares is 5751.8... 
Via Benzinga
News headline image
Mid-Day Market Update: Dow Surges 250 Points; LiqTech International Shares Slide ↗
U.S. stocks traded higher midway through trading, with the Dow Jones jumping 250 points on Thursday. The Dow traded up 0.75% to 34,617.38 while the NASDAQ rose 1.08% to 14,072.31... 
Via Benzinga
News headline image
34 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 37.7% to $4.64. Emclaire Financial Corp (NASDAQ: EMCF) shares climbed 32.8% to $38.35 after the company and... 
Via Benzinga
News headline image
Aptevo Therapeutics: Q4 Earnings Insights ↗
Aptevo Therapeutics (NASDAQ:APVO) reported its Q4 earnings results on Thursday, March 24, 2022 at 08:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
SEATTLE, WA / ACCESSWIRE / March 24, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its... 
From Aptevo Therapeutics
Via AccessWire
News headline image
60 Biggest Movers From Yesterday ↗
Gainers US Ecology, Inc. (NASDAQ: ECOL) shares surged 67.7% to close at $47.25 on Wednesday after Republic Services reported it will buy the company at $48 per share in cash.... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.